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Abstract
Purpose: To investigate the role of thioredoxin (TRX), a novel regulator of extracellular transglutaminase 2 (TG2), in
celiac patients IgA (CD IgA) mediated TG2 enzymatic activation.
Methods: TG2 enzymatic activity was evaluated in endothelial cells (HUVECs) under different experimental
conditions by ELISA and Western blotting. Extracellular TG2 expression was studied by ELISA and
immunofluorescence. TRX was analysed by Western blotting and ELISA. Serum immunoglobulins class A from
healthy subjects (H IgA) were used as controls. Extracellular TG2 enzymatic activity was inhibited by R281. PX12, a
TRX inhibitor, was also employed in the present study.
Results: We have found that in HUVECs CD IgA is able to induce the activation of extracellular TG2 in a dose-
dependent manner. Particularly, we noted that the extracellular modulation of TG2 activity mediated by CD IgA
occurred only under reducing conditions, also needed to maintain antibody binding. Furthermore, CD IgA-treated
HUVECs were characterized by a slightly augmented TG2 surface expression which was independent from
extracellular TG2 activation. We also observed that HUVECs cultured in the presence of CD IgA evinced decreased
TRX surface expression, coupled with increased secretion of the protein into the culture medium. Intriguingly,
inhibition of TRX after CD IgA treatment was able to overcome most of the CD IgA-mediated effects including the
TG2 extracellular transamidase activity.
Conclusions: Altogether our findings suggest that in endothelial cells CD IgA mediate the constitutive activation of
extracellular TG2 by a mechanism involving the redox sensor protein TRX.
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Introduction
Transglutaminase 2 (TG2) is a ubiquitously expressed highly
complex multifunctional protein with enzymatic, cell adhesion,
cell signaling and G-protein activities [1,2]. These functions of
TG2 are regulated by other proteins and cofactors, including
Ca2+ and GTP, and by the availability of these modulators in
different tissue compartments [3,4]. In the extracellular
environment, the abundance of Ca2+ and the low GTP/GDP
nucleotide concentrations may allow TG2 to act as an enzyme
modifying proteins at post-translational level by transamidation
or deamidation [5] while this activity is probably repressed in
the cytoplasm, where TG2 can act as a GTP-ase. Cell surface
TG2 is implicated in cell adhesion by protein-protein
interactions. As a transamidase, TG2 catalyzes the formation
of isopeptide bonds (ε-γ-glutamyl- lysine crosslink) between a
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selected glutamine residue on one substrate and a lysine
residue on another. In the absence of adequate concentrations
of any suitable amine substrate, TG2 deamidates the targeted
glutamine side chain, resulting in its conversion to glutamate
[6].
The enzymatic activity of TG2 is of research interest in that it
is implicated in the pathogenesis of a number of human
conditions, including celiac disease, a dietary gluten-induced
autoimmune-mediated enteropathy affecting HLA-DQ2 or HLA-
DQ8 subjects [7]. In celiac disease, TG2 enzymatic activity is
known to lead to the deamidation of gluten peptides, which
increases their affinity for HLA-DQ2 or HLA-DQ8 molecules [8].
This triggers an inflammatory T cell response ultimately
resulting in the destruction of the small-bowel mucosal
architecture [9]. Furthermore, during the disease pathogenesis
the patients mount an anti-TG2 autoantibody response [10].
These autoantibodies are present in the serum and in various
tissues in the patients, particularly in the small-intestinal
mucosa as deposits on the subepithelial basement membrane
and around capillary walls [11,12]. Intriguingly, the small-bowel
mucosal TG2 located at the sites where the antibodies bind
has been suggested to be catalytically active in untreated
celiac patients [13]. It has thus been proposed that celiac
disease-specific autoantibodies might account for the
enzymatic activation of small-bowel mucosal TG2, although
contrasting results are also reported [14].
Our previous studies have suggested that celiac IgA
increases TG2 enzymatic activity on endothelial cells, but the
mechanism involved has not yet been characterized [15,16].
Interestingly, it has recently been shown that thioredoxin
(TRX), a redox sensor protein in cells, is a novel regulator of
extracellular TG2 activity [17]. Therefore, the present aim was
thus to deepen the understanding of CD IgA-mediated TG2
enzymatic activation and to establish whether TRX might be a
key molecule in this process.
Materials and Methods
Cell Culture and Reagents
Human umbilical vein endothelial cells (HUVECs) were
purchased from Lonza (Cambrex Bio Science, Walkersville,
MD) and maintained in EGM-2 medium (Clonetics®, San
Diego, CA) with 2% fetal bovine serum (FBS) (Gibco
Invitrogen, Paisley, Scotland, UK) and 25 µg/mL endothelial
cell growth supplements (Clonetics). In all the experiments
performed, the cells were used between passages 2 and 6. A
non-reversible and cell-impermeable inhibitor for extracellular
TG2 activity, R281 [18], was used throughout at a final
concentration of 200 µM. In our experimental settings we
employed also the TRX inhibitor PX-12 (1-methylpropyl 2-
imidazolyl disulfide) at a non-toxic concentration of 1 µM
(TOCRIS, Bioscience, Ellisville, MI). All the chemical
compounds were administered 1h before addition of serum
IgA.
Purification of serum IgA class antibodies
Serum samples from nine biopsy-proven celiac disease
patients on a gluten-containing diet and five non-celiac healthy
controls were included in the present study. All celiac sera
were positive for anti-TG2 antibodies (titer ≥100 U/mL)
(Celikey®; Pharmacia Diagnostic GmbH, Freiburg, Germany)
and endomysial antibodies (titer 1≥1000), while all control sera
were negative. Total serum IgA from healthy donors (H IgA)
and celiac patient sera (CD IgA) were purified as previously
described [11] and diluted in PBS to a final concentration of
100 µg/mL. Purified IgA fractions, if not otherwise stated, were
used in all experiments at a concentration of 1 µg/ml.
Ethics Statement
The study protocol was approved by the Ethics Committee of
Tampere University Hospital, Tampere, Finland, and all
patients gave written informed consent.
TG2 activity assays
In order to determine the extracellular transamidating TG2
activity HUVECs were plated onto commercial fibronectin (FN)-
pre-coated 96-well plates (BD Biosciences Discovery Labware,
Bedford, MA) at a density of 2x105 cells per well and grown to
confluence. Thereafter, the cells were starved overnight (O/N)
in EGM-2 containing 1% of FBS followed by incubation in the
presence of different study compounds. At indicated time-
points the cells were washed with Hanks Balanced Salt
Solution (HBSS; Sigma Aldrich, St. Louis, MI), followed by
incubation with the TG2 substrate monodansylcadaverine
(MDC) (0.2 mM; Sigma Aldrich) for 2h at 37°C. Subsequently,
the wells were extensively washed and the layers fixed with 4%
paraformaldehyde (PFA) (Sigma Aldrich). TG2-mediated MDC
incorporation was detected using rabbit anti-dansyl antibody for
30 min at 37°C (1:1000; Invitrogen, Carlsbad, CA). A
secondary antibody, horseradish peroxidase-conjugated
polyclonal swine anti-rabbit immunoglobulin (1:2000; Dako,
Copenhagen, Denmark), was then added to the plates and
incubated for 30 min at 37°C. Finally, the peroxidase substrate
3,3’,5,5’-tetramethylbenzidine (TMB) (Slow Kinetic Form for
ELISA; Sigma Aldrich) was used and the enzymatic reaction
stopped with 2.5 M H2SO4. Absorbance was measured at 450
nm by spectrophotometer (Multiskan Ascent; Thermo
Labsystems, Waltham, MA). In order to demonstrate TG2-
specific incorporation of MDC, R281, was used.
Due to the fact that TG2 is ubiquitously expressed we further
investigated where the enzyme was activated, focusing on the
extracellular matrix environment. To this end, HUVECs grown
to confluence as described above, were dislodged from their
substratum by cell dissociation buffer (PBS, pH 7.4, with 2 mm
EDTA), leaving the cell-assembled matrix (ECM). Thereafter,
the plates were examined as described.
For Western blotting analyses of extracellular TG2 activity,
the ECM fractions, obtained upon EDTA treatment, were
directly solubilized by the addition of Laemmli gel loading
buffer. The samples were loaded and run on 12% SDS-PAGE
gels using the Bio-Rad Mini-Protein Tetra Cell system (Bio-Rad
Laboratories, Espoo, Finland). Proteins were transferred to
nitrocellulose filters (Hybond C-extra; Amersham Biosciences,
Little Chalfont, UK) and non-specific binding was blocked with
5% non-fat powdered milk for 1h at room temperature (RT).
The membranes were then incubated overnight (O/N) at +4°C
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with rabbit anti-dansyl antibody (1:10000; Invitrogen).
Thereafter, immunoreactivity was detected by consecutive
incubation of the membranes with polyclonal swine anti-rabbit
horseradish peroxidase (HRP)-conjugated secondary antibody
(Dako, Glostrup, Denmark) for 1h at RT. The bands were
visualized using the chemiluminescence detection system
(Amersham, ECL Plus Western Blotting Detection System,
Buckinghamshire, UK) and quantified by the Kodak 1D Image
analyses software (Kodak, New Haven, CT). As loading
control, γ-tubulin (GTU-88, Sigma Aldrich) was used. As above,
R281 was used to demonstrate TG2 specificity of MDC
incorporation.
Additionally, to investigate the relationship between the
transamidating extracellular TG2 activity and the amount of CD
IgA, we have designed a dose response test based on the
microtiter plate assay using live cells. Briefly, HUVECs were
plated on FN pre-coated 96-well plates (BD Biosciences
Discovery Labware) and cultured to confluence in EGM-2
medium. The day prior to the experiment, the cells were
starved O/N in EGM-2 medium (Clonetics) containing 1% FBS
(Gibco Invitrogen) and then treated with different CD IgA
concentrations (0.5 µg/mL; 1 µg/mL; 5 µg/mL; 25 µg/mL) for 3
h at 37°C, 5% CO2. Thereafter, in situ-TG2 activity was
investigated as described above except that the cells were not
removed from the plates using a modification of the in situ
assay by Verderio [19].
Quantification of extracellular TG2 expression on
endothelial cells
In order to investigate the extracellular surface expression of
TG2 by ELISA, HUVECs were grown to confluence on
commercial FN-pre-coated 96-well plates (BD Biosciences
Discovery Labware). After O/N starvation in EGM-2 with 1% of
FBS, the HUVECs were incubated for 24h in the presence of
different study compounds. The cells were then washed with
HBSS (Sigma Aldrich), fixed with 4% PFA (Sigma Aldrich) and
blocked with 5% BSA (Sigma Aldrich). The plates were
incubated either with mouse monoclonal antibody CUB7402
TG2 (NeoMarkers, Fremont, CA) or with an anti-TG2 antibody
recognizing the FN-binding domain, (clone 4G3, Millipore, MA)
for 1h at 37°C. Subsequently, the wells were extensively
washed and a specific secondary HRP-conjugated anti-mouse
immunoglobulins (1:2000; Dako) was added for 30 minutes at
37°C. Finally, the peroxidase substrate TMB (Sigma Aldrich)
was used and the enzymatic reaction was stopped with 2.5 M
H2SO4. The absorbance was measured at 450 nm by
spectrophotometer (Multiskan Ascent; Thermo Labsystems).
In vitro redox modulation of TG2 bound FN
In order to establish whether CD IgA is able to activate
oxidized inactive TG2 we used a modified protocol by
Stamnaes and coworkers [17]. The assay is based on the
knowledge that TG2 is sensitive to oxidative environments and
gradually loses activity upon handling and storage due to
oxidation [20]. In this system, Human FN 96-well MultiwellTM
(BD Bioscences, Bedford, Massachussets, USA) were coated
with 5µg/mL human recombinant TG2 (His-rhTG2) (Zedira
GmbH, Darmstadt, Germany) in Tris-buffered saline for 1h at
37°C. Enzymatic activity was measured by addition of 40 µM 5-
biotinamidopentylamine (5-BP) (Life Science Research Pierce
Biotechnology, Rockford, IL) under different sample conditions.
In the experiments Ca2+ was used at the concentration of 10
mM and dithiotreitol (DTT) at 1 mM. After extensive washings,
incorporated 5-BP was detected with streptavidin HRP-
conjugated secondary antibody (Life Science Research Pierce
Biotechnology). Lastly, the peroxidase substrate TMB (Sigma
Aldrich) was used and the enzymatic reaction stopped with 2.5
M H2SO4. Absorbance was measured at 450 nm by
spectrophotometer (Multiskan Ascent; Thermo Labsystems). In
order to verify that TG2 remained immobilized during the
procedure, some wells were incubated with CUB7402 (1:200)
(NeoMarkers, Fremont, CA) instead of 5-BP.
Binding of celiac autoantibodies to TG2 after redox
modulation
TG2 purified from guinea pig liver (5 µg/mL) (Sigma Aldrich)
was coated on microtiter plates (Maxisorp, Nunc A/S, Roskilde,
Denmark) for 1 hour at RT in Tris-buffered saline with 5 mM
CaCl2. After extensive washings with Tris-buffered saline with
10 mM EDTA and 0.1% Tween 20, the plates were treated with
100 µM 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) for 20
minutes, followed by incubation with 50 mM DTT for another 20
minutes and further washings. Serum samples from six celiac
patients diluted 1:200 or CUB7402 (1:16000) (NeoMarkers)
were added in triplicate for 30 minutes. Bound antibodies were
measured according to Sulkanen and coworkers [21].
Thioredoxin assay
The expression and release of thioredoxin was evaluated in
endothelial cells by ELISA and Western blotting. For ELISA,
HUVECs were plated onto commercial FN pre-coated 96-well
plates (BD Biosciences Discovery Labware) at a density of
1x104 cells per well. The cells were grown in complete culture
media until confluence and starved O/N before the assay.
Thereafter, the HUVECs were incubated with purified IgA class
antibodies from healthy donors and celiac patients for 24h at
37°C, with or without pre-incubation with different inhibitors.
The cells were then washed, fixed with 4% PFA (Sigma
Aldrich) and blocked in 2% BSA buffer. Surface expression of
thioredoxin on endothelial cells was detected by incubation of
the plates using mouse anti-thioredoxin antibody (1:200)
(sc-166393, Santa Cruz Biotechnology, Scotts Valley, CA) for
1h at 37°C, followed by incubation with the specific HRP-
conjugated secondary antibody (1:2000; Dako) Finally, the
peroxidase substrate TMB (Sigma Aldrich) was used and the
enzymatic reaction stopped with 2.5 M H2SO4. Absorbance was
measured at 450 nm by spectrophotometer (Multiskan Ascent;
Thermo Labsystems).
For Western blotting analyses, HUVECs were cultured in
complete endothelial growth medium in 24-well plate format
and starved in EGM-2 medium (Clonetics) with 1% FBS (Gibco
Invitrogen) O/N before the assay. The cells were then treated
for 24h with H IgA or with CD IgA, preceded by pre-incubation
with specific inhibitors, as described above. Thereafter, the
culture medium was collected, briefly centrifuged and
solubilized by addition of Laemmli buffer. Whole cell lysates
Celiac IgA Mediated TG2 Activation by Thioredoxin
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were obtained by direct solubilization and extraction of proteins
from cell monolayers in Laemmli buffer. Lastly, cell culture
supernatants and whole cell lysates were subjected to Western
blotting, using as primary antibodies mouse anti-TRX antibody
(1:2000) (Santa Cruz Biotechnology) and γ-tubulin (Sigma
Aldrich) as loading control. Immunoreactivity was detected as
above by sequential incubation of the membranes with
appropriate HRP-conjugated secondary antibody (Dako) for 1h
at RT. Visualization was by the chemiluminescence detection
system (Amersham), ECL Plus Western Blotting Detection
System) and quantification by the Kodak 1D Image analyses
software (Kodak).
Human INF-ƴ assay
Quantitative measurement of human INF-ƴ in culture
supernatants of endothelial cells under different experimental
conditions was implemented by an in vitro enzyme-linked
immunosorbent assay according to the manufacturer’s
instructions (Fisher Scientific, Waltham, MA).
Immunofluorescent stainings
HUVEC cells were cultured on FN-precoated chamber slides
(BD-Falcon™, Bedford, MA) under different experimental
conditions. The cells were then fixed in 4% PFA, washed with
PBS1x and blocked with 1% BSA. Immunolabelings were
carried out using as primary antibody anti-TG2 (diluted 1:50)
(clone 4G3, Millipore) detected by Alexa Fluor® 488-
conjugated secondary anti-mouse antibody (1:3000)
(Invitrogen, Molecular Probes™, Leiden, the Netherlands).
Stainings were visualized by fluorescent microscopy analysis
(Olympus Optical CO.Ltd BX60F5, Tokyo, Japan).
Statistical analysis
Statistical analysis was performed using the non-parametric
Mann–Whitney U-Test and the data were presented as mean
values. A p-value <0.05 was considered statistically significant.
Results
Effects of celiac IgA on endothelial cell extracellular
transglutaminase 2 transamidating activity and amount
In order to establish whether CD IgA increases the
endothelial cell extracellular transamidating activity of TG2 in a
time- and/or dose-dependent manner we performed an in situ
TG2 activity assay with confluent HUVECs monolayers starved
O/N. We observed that extracellular TG2 activity in HUVECs
was only present on addition of CD IgA but not when H IgA
was used (Figure 1A). With CD IgA extracellular TG2
enzymatic activity was already detectable after 3h of treatment.
Although at this time-point maximal activation of the enzyme
was observed, the induction was detectable at all-time points
considered. Pretreatment of the non-permeable, site-directed
TG2 inhibitor R281 abolished the increased extracellular TG2
transamidating activity induced by CD IgA throughout the
experiment. To study the dose-dependent relationship between
CD IgA-mediated extracellular TG2 activation, we added
different amounts of IgA, ranging from 0.5µg/mL to 25µg/mL, to
cultured endothelial cells. Interestingly, there was a dose-
dependent rise in extracellular TG2 enzymatic activity in
HUVECs incubated with increasing CD IgA concentrations
(Figure 1B). The maximal activity of 1.7-fold was reached with
5 µg/mL, after which no further increase was achieved. Inhibitor
R281 had no effect on the enzymatic activity when
administered (data not shown).
Since endothelial cells express high levels of TG2 on the cell
surface but also secrete it into their ECM, we sought further to
investigate the precise localization of the TG2 activity
stimulated by CD IgA. To this end, we studied TG2-mediated
incorporation of MDC into the ECM fractions laid down by
HUVECs, under different experimental conditions. We
identified a statistically significant increase in relative ECM-TG2
activity when CD IgA was administered to cultured endothelial
cells (Figure 2A). The observed effect was comparable to that
detected on cell monolayers over time. Further, we collected
deoxycolate-insoluble matrix protein under different
experimental conditions and subjected them to Western
blotting analyses in order to visualize MDC incorporation into
ECM (Figure 2B). We detected several bands spread over a
wide molecular weight range in all treatment groups. However,
in the ECM derived from endothelial cells incubated with CD
IgA there was an increase in the signal of low molecular mass
proteins when compared to control groups, as indicated by the
black circle in Figure 2B. In samples derived from cultures with
R281 and CD IgA the intensity of the 45 kDa band was clearly
reduced and similar to the controls.
As HUVECs in the presence of CD IgA are characterized by
increased extracellular TG2 transamidating activity, we sought
to ascertain whether this was associated with augmented
extracellular TG2 expression. The relative quantification of cell
surface-associated TG2 in non-permeabilized HUVECs with
4G3 demonstrated that in the presence of CD IgA there was a
1.1-fold increase in extracellular TG2 (Figure 3A and 3B).
Comparable results were achieved with CUB7402 which
recognizes a linear TG2 epitope (data not shown). Co-
administration of the non-reversible and cell impermeable
inhibitor for extracellular TG2 activity R281 was not able to
prevent this effect (Figure 3A and 3B).
Redox regulation of TG2 is important for the enzymatic
activation by CD IgA
As previous studies have shown that extracellular TG2
activity is sensitive to redox changes, we next investigated
whether the redox regulation of TG2 might also have an effect
on the ability of CD IgA to activate the enzyme. We observed
that in the absence of a reducing agent DTT and exogenous
Ca2+, TG2 was enzymatically inactive and both agents were
required for maximal activity (Figure 4A). The addition of CD
IgA or H IgA did not affect the transamidating TG2 activity
either in the presence or in the absence of both Ca2+ and DTT.
Interestingly, in the presence of DTT but without exogenous
Ca2+, CD IgA autoantibodies were able to induce enzymatic
activity of TG2 in contrast to H IgA. We also observed that
under oxidizing conditions induced by DTNB, reduced amounts
of CD IgA bind to the enzyme and that the process can be
reversed by treating the enzyme with DTT after DNTB and
Celiac IgA Mediated TG2 Activation by Thioredoxin
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Figure 1.  Endothelial extracellular transglutaminase 2 (TG2) activity analyses by monodansylcadaverine (MDC)
incorporation.  The relative extracellular TG2 activity (A) at different time points and with (B) increasing concentrations of class A
immunoglobulins are shown. The dashed line indicates TG2 activity in untreated endothelial cells (HUVECs). Bars represent mean
MDC incorporation as fold of control and error bars indicate standard error of the mean. P-value < 0.05 was considered significant
( **p<0.001 and *p<0.01). Data derived from three independent experiments, repeated in quadruplicate. HUVECs were treated with
celiac disease patient (CD IgA) and non-celiac subject’s immunoglobulin-A (H IgA). Extracellular TG2 activity was inhibited by
administering a non-permeable, site directed TG2 inhibitor, R281.
doi: 10.1371/journal.pone.0077277.g001
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before adding the antibodies. Neither DTNB nor DTT had any
effect on the binding of anti-TG2 monoclonal antibody
CUB7402, which recognizes a linear epitope (Figure 4B).
Celiac IgA-mediated activation of extracellular
transglutaminase 2 requires thioredoxin
Since we found that CD IgA mediated TG2 activation occurs
only under reducing conditions we sought to establish whether
the novel redox TG2 regulator TRX was involved in the process
as a physiological reducing agent. We found that the overall
TRX protein expression level to be comparable in all treatment
Figure 2.  Endothelial extracellular matrix (ECM) transglutaminase 2 (TG2) activity analyses by monodansylcadaverine
(MDC) incorporation.  (A) The relative ECM-TG2 activity at different time points by ELISA. The dashed line indicates TG2 activity
in untreated endothelial cells (HUVEC). Bars represent mean MDC incorporation as fold of control and error bars indicate standard
error of the mean. P-value < 0.05 was considered significant ( **p<0.001 and *p<0.01). Data derived from three independent
experiments, repeated in quadruplicate. (B) Western blotting analyses of endothelial ECM-TG2 activity measured by the
incorporation of MDC. Endothelial cells were treated with celiac disease patient (CD IgA) and non-celiac subject’s immunoglobulin-A
(H IgA). Extracellular TG2 activity was inhibited by administering a non-permeable, site directed TG2 inhibitor, R281.
doi: 10.1371/journal.pone.0077277.g002
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Figure 3.  Celiac patient immunoglobulins A (CD IgA) increase transglutaminase 2 (TG2) surface deposition on endothelial
cells.  (A) The relative surface expression of TG2 on non-permeabilized endothelial cells (HUVECs) was studied by ELISA. The
dashed line indicates TG2 surface expression in untreated HUVECs. Bars represent mean TG2 expression as fold of control and
error bars indicate standard error of the mean. P-value <0.05 was considered significant ( *p<0.001). Data derived from three
independent experiments, repeated in quadruplicate are shown. (B) Surface expression of TG2 on non-permeabilized HUVECs was
also investigated by immunofluorescence (IF) with the monoclonal TG2 antibody, 4G3. Representative IF stainings are shown.
Control non-celiac subject’s immunoglobulin-A (H IgA). Extracellular TG2 activity was inhibited by administering a site directed, non-
permeable inhibitor, R281.
doi: 10.1371/journal.pone.0077277.g003
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Figure 4.  Celiac disease IgA (CD IgA) can activate fibronectin-bound transglutaminase 2 (FN-TG2) under reducing
conditions.  The effect of CD IgA on TG2 enzymatic activity was assessed by EZ-Link Pentylamine-Biotin (5-BP) incorporation on
FN. In the absence of both the reducing agent, dithiothreitol (DTT) and Ca2+, TG2, alone or with any IgA, was enzymatically inactive.
Maximal TG2 activity was obtained in the presence of DTT and Ca2+ even in the presence of class A immunoglobulins. On the
contrary, in the presence of a reducing agent, DTT, but without exogenous Ca2+, CD IgA was able to induce the activation of TG2 in
contrast to non-celiac IgA (H IgA). Bars represent mean 5-BP incorporation on FN as fold of TG2 in the absence of DTT and Ca2+.
Error bars indicate standard error of the mean; P-value < 0.05 was considered significant ( ***p<0.001, **p<0.01 and *p<0.05). Data
derived from three independent experiments, repeated in quadruplicate are shown.
doi: 10.1371/journal.pone.0077277.g004
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groups (Figure 5A). On the other hand, endothelial cells
incubated with CD IgA secreted TRX into the cell cultured
media, whereas control cells did not. TRX secretion was
coupled to its decreased surface expression in CD IgA-treated
HUVECs (Figure 5B). It was of note that, co-administration of
the inhibitor for extracellular TG2 activity, R281, was not able to
prevent these effects exerted by CD IgA (Figure 5A and 5B).
In view of these observations, we next sought to establish
whether inhibition of extracellular TRX by PX12 might
counteract the effects of CD IgA autoantibodies observed on
Figure 5.  Celiac IgA (CD IgA) promotes secretion of thioredoxin.  (TRX) and decreases its endothelial surface expression.
(A) Representative Western blots from total cell lysates and supernatants show amounts of TRX and ƴ-tubulin used as loading
control for protein extracts. (B) Relative surface expression of TRX was studied by ELISA. The dashed line indicates TRX surface
expression in untreated HUVECs. Bars represent mean TRX expression as fold of control and error bars indicate standard error of
the mean. P-value <0.05 was considered significant ( *p<0.05 and **p<0.001). Data derived from three independent experiments,
repeated in quadruplicate are shown. Endothelial cells were treated with CD IgA and non-celiac subject’s immunoglobulin-A (H IgA).
Extracellular TG2 activity was inhibited by administering a site directed, non-permeable inhibitor, R281.
doi: 10.1371/journal.pone.0077277.g005
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HUVECs. Such seemed indeed to be the case, as pretreatment
of endothelial cultures with PX12 prevented the extracellular
TG2 activation mediated by CD IgA (Figure 6A). In addition to
this, inhibition of extracellular TRX with PX12 was able to
overcome the effects mediated by CD IgA on TG2 surface
expression and secretion of TRX into the culture supernatants
(Figure 6B and 6C).
Discussion
Our previous early studies indicated that CD IgA disturbs
angiogenesis, at least in vitro, presumably by increasing
extracellular TG2 transamidase activity, but the underlying
mechanism here is poorly understood [15,16]. Here we show
that the administration of CD IgA to confluent HUVEC
monolayers starved O/N, leads to an early and constitutive
activation of extracellular TG2 (Figures 1A and 2A).
Interestingly, we observed no time dependent correlation with
the transamidating activation of TG2 by CD IgA, as the
induction was detectable at all-time points examined (Figures
1A and 2A). We did, however, note a marked CD IgA dose-
dependent activation of extracellular TG2 (Figure 1B), in line
with previous work reporting dose-dependent enhancement of
TG2 transamidase activity by celiac autoantibodies [22]. The
correlation between the amount of disease-specific
autoantibodies and TG2 enzymatic activity has also been
documented in other previous articles [23,24], but with
contrasting outcomes as regards the activation of the protein.
In fact, both groups show that disease specific autoantibodies
had an inhibitory effect on TG2 enzymatic activity, this possibly
due to different experimental conditions [23,24].
In view of evidence which correlates increased extracellular
TG2 enzymatic activity with high TG2 expression levels
[19,25-27] we sought to investigate whether CD IgA-increased
extracellular TG2 transamidating activity was associated with
augmented cell surface TG2 presence. We have previously
shown that celiac disease autoantibodies do not up-regulate
the total TG2 protein expression level in endothelial cell lysates
[15]. In contrast, in endothelial cells treated with CD IgA
autoantibodies there was a small but statistically significant
increase in the relative TG2 presence on the cell surface
(Figure 3A and 3B) which nonetheless did not account for the
increased extracellular TG2 activity. This supports the
hypothesis that extracellular TG2 activation by CD IgA in
endothelial cell is a more complex and elaborate process
involving other important biological players. If the increased
extracellular TG2 expression in the presence of CD IgA has a
physiological significance or not, needs to be further
investigated.
Bearing in mind that TG2 is subject to oxidation and as a
result gradually loses activity upon handling and storage [20],
we examined how the reducing or oxidizing environmental
conditions might affect CD IgA-mediated modulation of TG2.
Interestingly, in an in vitro system, CD IgA was able of inducing
TG2 activation only in the presence of a reducing agent without
the addition of exogenous Ca2+ (Figure 4A), supporting the
conception that most probably their biological effects in
endothelial cells are exerted under a reducing extracellular
environment. Moreover, here we have shown that oxidation
alters the protein’s conformation in such ways that the
antigenic epitopes are less accessible and thus the reducing
environment helps maintain longer and more effective binding
of the antibodies to the TG2 antigen (Figure 4B). Recently, Jin
and co-workers [14] elegantly demonstrated in cell culture that
extracellular TG2 can be activated by the cellular secreted
redox protein TRX, which helps to keep the protein in an open
and active conformation. Interestingly, we found here that CD
IgA-treated HUVECs secreted TRX into the extracellular space
and that this was coupled with reduced surface expression of
the protein (Figure 5A and 5B), this suggesting that TRX might
have a role in CD IgA-mediated TG2 activation. Such
assumption was supported by our results in that pretreatment
of endothelial cultures with PX12 prevented the extracellular
TG2 activation mediated by CD IgA (Figure 6A). It is of note
that, PX 12, similarly to other alkylating agents [28], was able to
prevent TG2 enzymatic activity in the presence of Ca2+ and
DTT. Further to the above, we observed that the inhibition of
extracellular TRX by PX12 was able to prevent secretion of the
protein and to normalize TG2 surface expression in endothelial
cells treated with CD IgA but did not prevent its decrease from
the surface (data not shown). Previous works have shown that
the pro-inflammatory cytokine INF-γ can induce secretion of
TRX at levels capable of activating TG2 [29]. In contrast, our
findings exclude a role for INF-γ in the constitutive activation of
extracellular TG2 mediated by CD IgA, since this was not
detectable in our experimental settings (data not shown). In
summary, our data suggest that CD IgA mediates TG2
activation in the extracellular environment where the protein is
mainly inactive under physiological conditions [30], by a
mechanism involving the redox sensor protein TRX. In our
system, disease-specific autoantibody-induced INF-γ-
independent secretion of TRX probably helps to keep TG2 in a
conformation suitable for the constitutive antibody binding and
activation described in the present work. Intriguingly, the
decreased surface expression of TRX and the augmented TG2
expression on HUVECs may lead us to speculate that at the
cell surface TG2 might be present in a conformation which is
not suitable for the enzymatic activation mediated by CD IgA.
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Figure 6.  Celiac IgA CD IgA) mediated activation of extracellular transglutaminase 2 (TG2) by thioredoxin (TRX).  (A) The
relative surface expression of TG2 as well as (B) the relative TG2 activity on HUVECs treated with CD IgA autoantibodies was
investigated by ELISA prior preincubation of endothelial cells with TRX inhibitor, PX12. The dashed line indicates TG2 expression
and activity in untreated HUVECs. Bars represent mean values as fold of control and error bars indicate standard error of the mean.
P-value < 0.05 was considered significant ( *p<0.01 and **p<0.001). (C) The secretion of TRX in endothelial cell (HUVECs) culture
media was analysed by Western blotting in the presence of a specific TRX inhibitor, PX12 (1-methylpropyl 2-imidazolyl disulfide).
Representative Western blots of HUVECs culture supernatants show amounts of TRX and ƴ-tubulin used as loading control for
quality sample. Data derived from at least three independent experiments, repeated in quadruplicate are shown. Endothelial cells
were treated with CD IgA and non-celiac subject’s immunoglobulin-A (H IgA).
doi: 10.1371/journal.pone.0077277.g006
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